Prevention of vascular-allograft rejection by protecting the endothelial glycocalyx with immunosuppressive polymers

Nat Biomed Eng. 2021 Oct;5(10):1202-1216. doi: 10.1038/s41551-021-00777-y. Epub 2021 Aug 9.

Abstract

Systemic immunosuppression for the mitigation of immune rejection after organ transplantation causes adverse side effects and constrains the long-term benefits of the transplanted graft. Here we show that protecting the endothelial glycocalyx in vascular allografts via the enzymatic ligation of immunosuppressive glycopolymers under cold-storage conditions attenuates the acute and chronic rejection of the grafts after transplantation in the absence of systemic immunosuppression. In syngeneic and allogeneic mice that received kidney transplants, the steric and immunosuppressive properties of the ligated polymers largely protected the transplanted grafts from ischaemic reperfusion injury, and from immune-cell adhesion and thereby immunocytotoxicity. Polymer-mediated shielding of the endothelial glycocalyx following organ procurement should be compatible with clinical procedures for transplant preservation and perfusion, and may reduce the damage and rejection of transplanted organs after surgery.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Allografts
  • Animals
  • Glycocalyx*
  • Graft Rejection* / prevention & control
  • Immunosuppressive Agents
  • Mice
  • Polymers

Substances

  • Immunosuppressive Agents
  • Polymers

Grants and funding